Loading...

Welcome to N4 Pharma

We’re N4 Pharma, a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.

Watch our video animation below to see Nuvec® in action:

Information for investors

Are you an investor? Visit the dedicated area of the website to view information on the AIM rule 26, company presentations and reports. The latest regulatory news updates are also available.

View investor information

Nuvec® is a unique, non-viral adjuvant delivery system that has the potential to revolutionise vaccines and cancer treatments. It’s currently in the pre-clinical phase and you can download our whitepaper to read all about its mode of action, plus watch our Nuvec® animation!

Latest news and updates

N4 Pharma Oncology programme initial pilot study

December 20th, 2021|

N4 Pharma has successfully completed an in vivo confirmatory oncology study which reinforces the results from an earlier pilot study designed to test the ability to use a monodispersed Nuvec® formulation in an intravenous ("i.v") [...]

Article: Next gen drug delivery technologies

October 27th, 2021|

"The development of smart drug delivery systems will improve drug efficacy, reduce costs, and improve storage, and ultimately lead to better treatments for the patient.” N4 Pharma’s CEO, Nigel Theobald, is featured in this month’s [...]